Company news

Absci Corporation news in 2025

Absci Corporation's news releases, calls and decks from 2025, newest first.

View company

Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

December 10, 2025

Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

December 9, 2025

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

December 3, 2025

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

November 11, 2025

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

October 28, 2025

Absci to Participate in Upcoming Investor Conferences

October 26, 2025

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

October 14, 2025

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

September 10, 2025

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

August 24, 2025

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

August 11, 2025

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

August 6, 2025

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

July 29, 2025

Absci Announces Proposed Public Offering of Common Stock

July 23, 2025

Absci Announces Pricing of Public Offering of Common Stock

July 23, 2025

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

July 6, 2025

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

May 12, 2025

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

May 12, 2025

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

April 13, 2025

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

March 17, 2025

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

March 3, 2025

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

March 3, 2025

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2025

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

February 17, 2025

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

January 21, 2025

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

January 9, 2025

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

January 7, 2025

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

January 5, 2025

Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025